Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC

Zhang, Fan; Guo, Wei; Zhou, Bolun; Wang, Shuhang; Li, Ning; Qiu, Bin; Lv, Fang; Zhao, Liang; Li, Jian; Shao, Kwang‐Tsao; Xue, Qi; Gao, Shugeng

doi:10.1016/j.jtho.2022.04.012

Cited by 46 publications

(30 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…So the better postoperative pathological response from neoadjuvant PD-1 inhibitor combined with chemotherapy may translate into a long-term survival benefit. This has been confirmed in the neoadjuvant immunotherapy of lung cancer ( 40 – 43 ).…”

Section: Discussionmentioning

confidence: 62%

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma

Huang²,

Li³

et al. 2023

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

BackgroundNeoadjuvant programmed death receptor-1 (PD-1) inhibitor combined with chemotherapy has been reported to improve the pathological response of locally advanced esophageal squamous cell carcinoma (ESCC), but the systematic report on survival follow-up is quite few. This study we will report the survival follow-up outcomes after a median follow-up of 21.1 months.MethodsThis was a real-world retrospective study. Locally advanced ESCC patients treated with neoadjuvant sintilimab combined with albumin-bound paclitaxel and nedaplatin followed by surgery and completed at least 1-year follow-up were reviewed. The primary outcome was disease-free survival (DFS) at 24 months. The secondary outcome was overall survival (OS) at 24 months.ResultsNinety eligible patients were included in the analysis between July 2019 and October 2021. The median number of neoadjuvant cycles was 3 (range 2-4). All patients achieved R0 resection. With a median follow-up of 21.1 months (range 14.0-39.0), the median DFS and median OS had not reached, 2-year DFS rate was 78.3% (95%CI 68.8%-89.1%) and 2-years OS rate was 88.0% (95%CI 80.6%-96.0%). Postoperative pathological stage, pCR, MPR, tumor down-staging were significantly correlated with favorable survival outcome. Univariable and multivariable Cox regression analysis identified cycle number of neoadjuvant treatment as independent predictor of DFS.ConclusionOur results preliminarily show a survival benefit of neoadjuvant sintilimab combined with chemotherapy in locally advanced ESCC.

show abstract

Section: Discussionmentioning

confidence: 62%

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma

Huang²,

Li³

et al. 2023

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The patient declined adjuvant target therapy and resumed sintilimab 200 mg every three weeks. Sintilimab is a recombinant humanized anti-PD-1 monoclonal antibody; previous studies have validated its safety and efficacy in other tumor species [18,19]. This is the first application of sintilimab in thyroid cancer treatment as an alternative anti-PD-1 antibody besides pembrolizumab.…”

Section: Discussionmentioning

confidence: 93%

Pathologic complete response after neoadjuvant v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibition combined with immunotherapy therapy for anaplastic thyroid carcinoma: a case report and literature review

et al. 2023

View full text Add to dashboard Cite

Anaplastic thyroid carcinoma (ATC) is a highly malignant tumor with invasive nature. Most patients present with locally advanced and/or distant metastatic diseases that are difficult to treat. We report a case of a previously inoperable patient with v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutated ATC. After a trial of neoadjuvant Dabrafenib/ Trametinib with immunotherapy, the tumor became operable, and surgical pathology indicated a pathologic complete response (pCR). We also reviewed cases from the literature that utilized neoadjuvant BRAF-directed therapy in ATCs. These cases emphasize that BRAF-and immune-directed therapy is a feasible option in patients with inoperable ATC and may lead to improved outcomes.

show abstract

“…In CheckMate 816, the neoadjuvant treatment of nivolumab plus chemotherapy improved the pCR rate (24.0% vs. 2.2%) in resectable NSCLC patients, and median OS showed a beneficial trend ( 57 ). In a neoadjuvant study of sintilimab combined with chemotherapy, 40.5% and 10.8% of patients attained MPR and pCR, respectively, and 3-year OS and disease-free survival (DFS) rates were 95.5% and 81.8%, respectively ( 58 ). In our study, we found that the MPR rate of patients with neoadjuvant immunotherapy was 58.4% and the pCR rate was 38.9%, which was similar to the above studies.…”

Section: Discussionmentioning

confidence: 99%

Assessing the efficacy of immunotherapy in lung squamous carcinoma using artificial intelligence neural network

Li²,

Ma³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundAt present, immunotherapy is a very promising treatment method for lung cancer patients, while the factors affecting response are still controversial. It is crucial to predict the efficacy of lung squamous carcinoma patients who received immunotherapy.MethodsIn our retrospective study, we enrolled lung squamous carcinoma patients who received immunotherapy at Beijing Chest Hospital from January 2017 to November 2021. All patients were grouped into two cohorts randomly, the training cohort (80% of the total) and the test cohort (20% of the total). The training cohort was used to build neural network models to assess the efficacy and outcome of immunotherapy in lung squamous carcinoma based on clinical information. The main outcome was the disease control rate (DCR), and then the secondary outcomes were objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).ResultsA total of 289 patients were included in this study. The DCR model had area under the receiver operating characteristic curve (AUC) value of 0.9526 (95%CI, 0.9088–0.9879) in internal validation and 0.9491 (95%CI, 0.8704–1.0000) in external validation. The ORR model had AUC of 0.8030 (95%CI, 0.7437–0.8545) in internal validation and 0.7040 (95%CI, 0.5457–0.8379) in external validation. The PFS model had AUC of 0.8531 (95%CI, 0.8024–0.8975) in internal validation and 0.7602 (95%CI, 0.6236–0.8733) in external validation. The OS model had AUC of 0.8006 (95%CI, 0.7995–0.8017) in internal validation and 0.7382 (95%CI, 0.7366–0.7398) in external validation.ConclusionsThe neural network models show benefits in the efficacy evaluation of immunotherapy to lung squamous carcinoma patients, especially the DCR and ORR models. In our retrospective study, we found that neoadjuvant and adjuvant immunotherapy may bring greater efficacy benefits to patients.

show abstract

Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC

Cited by 46 publications

References 43 publications

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma

Pathologic complete response after neoadjuvant v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibition combined with immunotherapy therapy for anaplastic thyroid carcinoma: a case report and literature review

Assessing the efficacy of immunotherapy in lung squamous carcinoma using artificial intelligence neural network

Contact Info

Product

Resources

About